Kolexia
Dalenc Florence Oncologie médicale
Dalenc Florence
Oncologie médicale
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
385 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Récidive tumorale locale Tumeur du sein de l'homme Cellules tumorales circulantes Carcinomes Tumeurs du cerveau Cancers du sein inflammatoires

Collaborateurs

Voir plus
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Goncalves Anthony
Goncalves Anthony
Centre Paoli-Calmettes, Marseille, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France

Industries

Voir plus
AstraZeneca
9 collaboration(s)
Dernière en 2023
Pfizer
9 collaboration(s)
Dernière en 2023
Lilly
6 collaboration(s)
Dernière en 2023
CanceroDigest
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
EUTACAM: Pilot Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   20 mars 2024
ELAINEIII: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Essai Clinique (Sermonix Pharmaceuticals Inc.)   07 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study
Essai Clinique (MedSIR)   15 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
SAFIR02_Breast: PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Essai Clinique (Unicancer)   09 janvier 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
British journal of cancer   05 janvier 2024
EMERALD: Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Essai Clinique (Stemline Therapeutics, Inc.)   04 décembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
TROPiCS-02: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens
Essai Clinique (Gilead)   17 novembre 2023